Over thirty-six million individuals are infected with HIV worldwide. Nearly 95 per cent of these individuals are infected with HIV type 1 (HIV-1), which has a high rate of viral mutation that helps drive immune evasion, disease progression, and rapid emergence of drug resistance. HIV type 2 (HIV-2) accounts for fewer than two million infections overall, remains primarily restricted to West Africa, and exhibits a significantly attenuated disease phenotype compared to HIV-1, characterized by lower rates of transmissibility and a slower progression to AIDS. HIV-2 has recently been found to have a significantly lower rate of mutation compared with HIV-1, which may be related to the differences in viral disease progression and persistence. Although the main driver of HIV mutagenesis is the low fidelity of the virally encoded reverse transcriptase, host factors may contribute to the mutation rate as well. The host protein SAMHD1 has been previously shown to restrict HIV-1 infection in myeloid lineage cells by depletion of dNTP pools through a triphosphohydrolase activity. In addition to inhibiting reverse transcription, this disruption of cellular dNTP levels may contribute to mis-incorporation of nucleotides and result in mutation of the virus. Here, we propose the use of NGS to explore the role of SAMHD1 on HIV-1 and HIV-2 mutagenesis. Using HIV-1 and HIV-2 Vpx-viruses (which are sensitive to SAMHD1 restriction), we will use high-throughput sequencing to observe how SAMHD1 expression alters the mutational profile (frequency and spectra) of integrated proviruses. We will explore how mutation rates of HIV-2 can be manipulated through the use of nucleoside analogs and RNRI drugs to explore what effects these compounds have on the HIV-2 mutation profile. Using single-cycle infectivity assays as well as long-term spreading experiments, we will be able to correlate mutagenesis with viral evolution and infectivity data to explore how sensitive these two viruses are to changes in viral mutation. This work will serve to understand how HIV-2 operates at a lower mutation frequency than HIV-1, elucidate the relationship between mutagenesis and infectivity for the two viruses, and provide insights into the contrasting phenotypes observed between the viruses.
